Targeting microtubule dynamics to treat advanced prostate cancer
Targeted Suppression of Microtubule Dynamics for Treatment of Metastatic Castration-Resistant Prostate Cancer
['FUNDING_R01'] · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · NIH-11167485
This study is testing a new treatment for men with advanced prostate cancer that doesn't respond to hormone therapy, using special molecules that target cancer cells to help improve the effectiveness of the therapy while protecting healthy tissue, and you might have a chance to join the trials to see how well it works.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11167485 on ClinicalTrials.gov |
What this research studies
This research aims to develop a new targeted therapy for metastatic castration-resistant prostate cancer (mCRPC), a condition with limited treatment options and poor survival rates. The approach focuses on utilizing small molecules that specifically bind to the prostate-specific membrane antigen (PSMA), which is overexpressed in cancerous prostate tissue. By employing advanced radionuclide therapy, the research seeks to enhance the effectiveness of treatment while minimizing damage to non-cancerous tissues. Patients may have the opportunity to participate in trials that evaluate the safety and efficacy of these innovative therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with metastatic castration-resistant prostate cancer who have not responded adequately to existing therapies.
Not a fit: Patients with early-stage prostate cancer or those who are not castration-resistant may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced prostate cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results with similar targeted therapies, but this specific approach is still being evaluated for its effectiveness.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: AZHDARINIA, ALI — UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
- Study coordinator: AZHDARINIA, ALI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: advanced prostate cancer, androgen independent prostate cancer, androgen indifferent prostate cancer, androgen insensitive prostate cancer, androgen resistance in prostate cancer